NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a quarterly dividend on Thursday, February 20th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 5.01%. View AbbVie's Dividend History.

AbbVie declared that its Board of Directors has approved a stock repurchase program on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings data on Friday, February, 7th. The company reported $2.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.19 by $0.02. The company had revenue of $8.70 billion for the quarter, compared to the consensus estimate of $8.68 billion. AbbVie had a negative return on equity of 162.37% and a net margin of 23.69%. The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for AbbVie.

AbbVie updated its FY20 earnings guidance on Friday, February, 7th. The company provided EPS guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.78.

14 analysts have issued twelve-month price objectives for AbbVie's shares. Their forecasts range from $66.61 to $105.00. On average, they expect AbbVie's stock price to reach $89.30 in the next twelve months. This suggests that the stock has a possible downside of 5.2%. View Analyst Price Targets for AbbVie.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AbbVie.

News headlines about ABBV stock have been trending extremely negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AbbVie earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (5.86%), State Street Corp (4.65%), FMR LLC (2.72%), Geode Capital Management LLC (1.65%), Bank of New York Mellon Corp (1.02%) and Renaissance Technologies LLC (0.80%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Schroder Investment Management Group, Capital International Investors, Skandinaviska Enskilda Banken AB publ , Victory Capital Management Inc., Levin Easterly Partners LLC, Bank of New York Mellon Corp and Bank of Montreal Can. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Janus Henderson Group PLC, Farallon Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Amundi Pioneer Asset Management Inc., MERIAN GLOBAL INVESTORS UK Ltd and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $94.23.

AbbVie has a market capitalization of $139.35 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.